EUVIMEDSkopri EUVIMED
Crossref

Screening for Predictive Factors of Efficacy of Second‐Generation Androgen Receptor Axis‐Targeted Agents in Patients With High‐Risk Metastatic Hormone‐Sensitive Prostate Cancer

Takashi Ueda iD, Keita Hayakawa, Go Horiguchi, Junki Murashita, Takumi Shiraishi, Saizo Fujimoto, Masatsugu Miyashita, Yumiko Saito, Yusuke Gabata, Satoshi Sako, Hikaru Takahashi, Atsuko Fujihara and 7 more

The Prostate · 2025-05 · 85 (6) · 524-530

DOI: 10.1002/pros.24855 ↗

At a glance

Journal article in The Prostate, published online on 2025-01-15. Written by Takashi Ueda and 18 co-authors. Institution: Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan. Major MEDLINE topics: Prostatic Neoplasms, Receptors, Androgen, Androgen Receptor Antagonists. Cited 11 times so far (Crossref); 17 references. Funded by: The authors received no specific funding for this work..

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Differences in the effectiveness of second‐generation androgen receptor axis‐targeted agents (ARATs) in high‐risk metastatic hormone‐sensitive prostate cancer (mHSPC) remain unclear. This study aimed to identify the factors influencing the efficacy of ARATs in patients with high‐risk mHSPC and compare their long‐term effectiveness.

Methods

Four hundred and sixty‐six patients with mHSPC treated with ARATs were retrospectively recruited from our hospital and affiliated hospitals of the Kindai Oncology Study Group and Kyoto Prefectural University of Medicine Oncology Study Group between December 2013 and March 2024. Cox proportional hazards analysis was performed to identify prognostic factors for overall survival in patients with mHSPC. Propensity score matching was used to adjust for the differences in clinical backgrounds of the patients.

Results

Univariate and multivariable analyses revealed that Gleason pattern 5 and pretreatment ALP levels were notable prognostic factors for overall survival in patients with mHSPC treated with ARATs. In the subgroup of patients with high‐risk mHSPC with Gleason pattern 5, apalutamide and enzalutamide showed significantly better outcomes in terms of PSA‐PFS, PFS2, and overall survival compared to abiraterone acetate though selection bias and the small number of patients may be associated with the results in this study. Univariate and multivariable analyses suggested that ARATs selection (ABI vs. APA or ENZ) may serve as an independent predictor of overall survival in patients with high‐risk mHSPC with Gleason pattern 5 treated with ARATs.

Conclusion

Gleason pattern 5 may be a predictive factor for ARAT efficacy in patients with high‐risk mHSPCs.

Subjects

MeSH terms (MEDLINE)

Prostatic NeoplasmsReceptors, AndrogenAndrogen Receptor AntagonistsHumansMaleAgedRetrospective StudiesBenzamidesMiddle AgedNitrilesPhenylthiohydantoinThiohydantoinsPrognosisTreatment OutcomeProstate-Specific AntigenNeoplasm GradingNeoplasm Metastasis

Author keywords

Gleason pattern 5abiraterone acetateapalutamideenzalutamidemetastatic hormone‐sensitive prostate cancer

Substances

BenzamidesenzalutamideNitrilesPhenylthiohydantoinReceptors, AndrogenapalutamideThiohydantoinsAndrogen Receptor AntagonistsProstate-Specific AntigenAR protein, human

Authors and institutions

  • Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Biostatistics, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Urology, Kindai Unversity Faculty of Medicine, Sayama, Japan.
  • Department of Urology, Kindai University Nara Hospital, Nara, Japan.
  • Department of Urology, Maizuru Kyosai Hospital, Maizuru, Japan.

ORCID profiles: Takashi Ueda, Takafumi Minami, Yutaka Yamamoto, Masayoshi Okumi, Osamu Ukimura

Funding

  • The authors received no specific funding for this work.

Cite

APA

Ueda, T., Hayakawa, K., Horiguchi, G., Murashita, J., Shiraishi, T., Fujimoto, S., Miyashita, M., Saito, Y., Gabata, Y., Sako, S., Takahashi, H., Fujihara, A., Minami, T., Yamamoto, Y., Okumi, M., Hongo, F., Okihara, K., Fujita, K., & Ukimura, O. (2025). Screening for Predictive Factors of Efficacy of Second‐Generation Androgen Receptor Axis‐Targeted Agents in Patients With High‐Risk Metastatic Hormone‐Sensitive Prostate Cancer. The Prostate, 85(6), 524-530. https://doi.org/10.1002/pros.24855

Vancouver

Ueda T, Hayakawa K, Horiguchi G, Murashita J, Shiraishi T, Fujimoto S, et al. Screening for Predictive Factors of Efficacy of Second‐Generation Androgen Receptor Axis‐Targeted Agents in Patients With High‐Risk Metastatic Hormone‐Sensitive Prostate Cancer. The Prostate. 2025;85(6):524-530. doi:10.1002/pros.24855

BibTeX
@article{Ueda2025,
  author = {Ueda, Takashi and Hayakawa, Keita and Horiguchi, Go and Murashita, Junki and Shiraishi, Takumi and Fujimoto, Saizo and Miyashita, Masatsugu and Saito, Yumiko and Gabata, Yusuke and Sako, Satoshi and Takahashi, Hikaru and Fujihara, Atsuko and Minami, Takafumi and Yamamoto, Yutaka and Okumi, Masayoshi and Hongo, Fumiya and Okihara, Koji and Fujita, Kazutoshi and Ukimura, Osamu},
  title = {Screening for Predictive Factors of Efficacy of Second‐Generation Androgen Receptor Axis‐Targeted Agents in Patients With High‐Risk Metastatic Hormone‐Sensitive Prostate Cancer},
  journal = {The Prostate},
  year = {2025},
  volume = {85},
  number = {6},
  pages = {524--530},
  doi = {10.1002/pros.24855}
}
Start for free →